COEPW (COEPW) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-01

Key Insights

Z Squared Inc. (formerly Coeptis Therapeutics) is acquiring Skycore Digital LLC, a data center company, for up to $22 million in Series B Convertible Preferred Stock, signaling a significant strategic pivot from therapeutics to digital infrastructure.
The Series B Preferred Stock includes aggressive terms for investors: 8-10% annual dividends, conversion at 110% of VWAP, forced conversion at 200% of conversion price, and a mandatory redemption in 7 years, indicating the company is willing to accept substantial dilution and financial obligations.
The transaction has a tight 90-day exclusivity period with a June 30, 2026 drop-dead date and a $500,000 break-up fee, suggesting execution risk and potential complications in deal closure.
The company is simultaneously issuing equity to consultants and service providers (200,000 shares to Group 10 Holdings and up to 566,000 shares to Moneta Advisory Partners), which increases shareholder dilution during an active acquisition period.

Want the newest filings?

This analysis covers the filing from 2026-05-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-30

Coeptis Therapeutics completed a reverse merger with Z Squared Inc. on April 24, 2026, resulting in a corporate restructuring where Coeptis became the parent holding company and Z Squared became a wholly owned subsidiary, with both entities changing their names in the process.
The filing indicates significant changes in control and corporate governance, including amendments to the certificate of incorporation and potential changes in directors and executive officers that warrant careful review of management continuity and strategic direction.
The document contains extensive forward-looking statements and risk factors, suggesting the combined entity faces material uncertainties and substantial known and unknown risks that could materially impact future results and performance.

Filed: 2026-04-28

Coeptis Therapeutics completed a business combination with Z Squared, Inc. (NASDAQ: ZSQR), with the company now trading under ticker ZSQR on Nasdaq Global Market, representing a significant corporate restructuring event.
The filing indicates a pro rata dividend distribution related to Coeptis's pre-business combination biopharmaceutical business, suggesting a separation or spin-off of assets post-merger that could impact shareholder value allocation.
This is a routine 8-K disclosure (Item 8.01) of a press release supplementing information about the already-announced business combination, with no material new financial data or operational details provided in the filing itself.

Filed: 2026-04-24

Coeptis Therapeutics completed a business combination with Z Squared Inc., a material corporate event that fundamentally changes the company's structure and operations.
The company's ticker symbol is changing from COEP to ZSQR effective Monday, April 27, 2026, requiring investors to update their portfolio tracking and trade under the new symbol.
Trading is expected to commence on Nasdaq Global Market (upgraded from Nasdaq Capital Market), suggesting improved liquidity and market tier status post-combination.
This is a Regulation FD disclosure filing, meaning the press release is furnished but not filed, limiting certain legal protections and incorporation-by-reference provisions for investors.

Filed: 2026-04-08

Coeptis Therapeutics Holdings, Inc. announced that Nasdaq has approved the listing of the post-merger company's common stock on the Nasdaq Global Market under the ticker symbol 'ZSQR', subject to customary closing conditions.
The company is an emerging growth company and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
Investors should closely monitor any further updates on the proposed merger with Z Squared Inc. and the company's plans for its listing on the Nasdaq Global Market.

Other reports for COEPW

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.